Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders? - Archive ouverte HAL Access content directly
Journal Articles Current Rheumatology Reports Year : 2021

Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders?

(1) , (1, 2) , (3, 4) , (3) , (5, 6) , (1) , (1) , (1, 2) , (1, 2)
1
2
3
4
5
6

Abstract

Purpose of review: COVID-19 patients have a procoagulant state with a high prevalence of thrombotic events. The hypothesis of an involvement of antiphospholipid antibodies (aPL) has been suggested by several reports. Here, we reviewed 48 studies investigating aPL in COVID-19 patients. Recent findings: Prevalence of Lupus Anticoagulant (LA) ranged from 35% to 92% in ICU patients. Anti-cardiolipin (aCL) IgG and IgM were found in up to 52% and up to 40% of patients respectively. Anti-β2-glycoprotein I (aβ2-GPI) IgG and IgM were found in up to 39% and up to 34% of patients respectively. Between 1% and 12% of patients had a triple positive aPL profile. There was a high prevalence of aβ2-GPI and aCL IgA isotype. Two cohort studies found few persistent LA but more persistent solid phase assay aPL over time. aPL determination and their potential role is a real challenge for the treatment of this disease.

Dates and versions

hal-03464237 , version 1 (03-12-2021)

Identifiers

Cite

Thomas Foret, Virginie Dufrost, Lucie Salomon Du Mont, Patricia Costa, Benjamin Lefevre, et al.. Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders?. Current Rheumatology Reports, 2021, 23 (8), pp.65. ⟨10.1007/s11926-021-01029-3⟩. ⟨hal-03464237⟩
38 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More